Vianello Andrea, De Vita Nello, Scotti Lorenza, Guarnieri Gabriella, Confalonieri Marco, Bonato Valeria, Molena Beatrice, Maestrone Carlo, Airoldi Gianluca, Olivieri Carlo, Sainaghi Pier Paolo, Lionello Federico, Arcaro Giovanna, Della Corte Francesco, Navalesi Paolo, Vaschetto Rosanna
Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Gallucci, 13, 35121 Padova, Italy.
Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy.
J Clin Med. 2022 Mar 2;11(5):1372. doi: 10.3390/jcm11051372.
As the clinical outcome of octogenarian patients hospitalised for COVID-19 is very poor, here we assessed the clinical characteristics and outcomes of patients aged 80 year or older hospitalised for COVID-19 receiving non-invasive respiratory support (NIRS). A multicentre, retrospective, observational study was conducted in seven hospitals in Northern Italy. All patients aged ≥80 years with COVID-19 associated hypoxemic acute respiratory failure (hARF) undergoing NIRS between 24 February 2020, and 31 March 2021, were included. Out of 252 study participants, 156 (61.9%) and 163 (64.6%) died during hospital stay and within 90 days from hospital admission, respectively. In this case, 228 (90.5%) patients only received NIRS (NIRS group), while 24 (9.5%) were treated with invasive mechanical ventilation (IMV) after NIRS failure (NIRS+IMV group). In-hospital mortality did not significantly differ between NIRS and NIRS+IMV group (61.0% vs. 70.8%, respectively; = 0.507), while survival probability at 90 days was significantly higher for NIRS compared to NIRS+IMV patients (0.379 vs. 0.147; 0.0025). The outcome of octogenarian patients with COVID-19 receiving NIRS is quite poor. Caution should be used when considering transition from NIRS to IMV after NIRS failure.
由于因新冠肺炎住院的八旬患者临床结局非常差,我们在此评估了因新冠肺炎住院并接受无创呼吸支持(NIRS)的80岁及以上患者的临床特征和结局。在意大利北部的七家医院进行了一项多中心、回顾性、观察性研究。纳入了2020年2月24日至2021年3月31日期间所有年龄≥80岁、患有新冠肺炎相关低氧性急性呼吸衰竭(hARF)并接受NIRS的患者。在252名研究参与者中,分别有156名(61.9%)和163名(64.6%)在住院期间和入院后90天内死亡。在此情况下,228名(90.5%)患者仅接受了NIRS(NIRS组),而24名(9.5%)在NIRS失败后接受了有创机械通气(IMV)治疗(NIRS+IMV组)。NIRS组和NIRS+IMV组的院内死亡率无显著差异(分别为61.0%和70.8%;P = 0.507),而NIRS组患者90天时的生存概率显著高于NIRS+IMV组患者(0.379对0.147;P = 0.0025)。接受NIRS的新冠肺炎八旬患者结局相当差。在考虑NIRS失败后从NIRS过渡到IMV时应谨慎。